Last updated: September 29, 2026
The polyethylene glycol 3350, sodium chloride, potassium chloride and sodium bicarbonate combination is a prescription bowel-cleansing formulation used before colonoscopy and other gastrointestinal procedures. Its commercial value is concentrated in formulation execution rather than core molecule protection. The formulation has a mature generic market, limited traditional patent barriers and meaningful opportunities in taste, volume reduction, preparation time, renal-risk positioning, packaging and manufacturing efficiency.
What is polyethylene glycol 3350 with electrolytes used for?
The combination is an osmotic bowel preparation. Polyethylene glycol 3350 retains water in the intestinal lumen, while sodium chloride, potassium chloride and sodium bicarbonate help maintain an approximately isotonic electrolyte solution and reduce clinically significant electrolyte shifts during high-volume lavage.[1]
A representative 4-liter GoLYTELY formulation contains:
| Ingredient |
Approximate quantity per 4 liters |
Functional role |
| Polyethylene glycol 3350 |
236 g |
Osmotic laxative and water-retention agent |
| Sodium chloride |
5.84 g |
Sodium and chloride replacement |
| Potassium chloride |
2.98 g |
Potassium replacement |
| Sodium bicarbonate |
6.74 g |
Bicarbonate buffering and electrolyte contribution |
| Flavor system |
Product-specific |
Palatability and patient adherence |
The ingredients are listed as active ingredients in the prescription product rather than as conventional inactive excipients. The excipient strategy applies primarily to flavorants, sweeteners, solubilizers, packaging materials and physical presentation.
The product is generally supplied as a powder for reconstitution. The patient adds water to produce approximately four liters of solution and consumes the preparation according to the prescribing instructions.[1]
What is the FDA regulatory status of this bowel-prep formulation?
The combination is an FDA-approved prescription bowel preparation. GoLYTELY was approved under NDA 018316 and has been marketed for decades. The formulation is regulated as a drug product rather than an over-the-counter laxative when used as a colonoscopy preparation.[2]
The regulatory profile is commercially favorable for generic entrants:
- The active ingredients are established pharmaceutical substances.
- The product is a conventional aqueous oral solution after reconstitution.
- Bioequivalence is generally assessed through pharmaceutical equivalence and relevant product-quality requirements rather than systemic pharmacokinetic exposure.
- Manufacturing requires control of powder uniformity, dissolution, microbial quality, assay and electrolyte composition.
- Labeling must address contraindications, dehydration, aspiration, electrolyte abnormalities and gastrointestinal obstruction risks.
For an abbreviated new drug application, the principal technical burden is formulation and manufacturing equivalence. A sponsor must demonstrate that its product has the same active ingredients, dosage form, strength, route of administration and labeling elements required for pharmaceutical equivalence.[3]
What is the Orange Book status of GoLYTELY?
GoLYTELY is a mature prescription product with no meaningful remaining new chemical entity exclusivity. Its commercial competition comes from generic polyethylene glycol-electrolyte solutions and alternative bowel-prep products.
The FDA Orange Book is the controlling source for current patent and exclusivity listings. For a mature product of this age, the principal commercial issue is generally whether any current listed formulation, method-of-use or pediatric-exclusivity entry remains relevant to the proposed ANDA, not whether the original product has an active compound patent.[4]
The practical conclusion is that market access depends more on ANDA readiness, product quality, supply reliability and contracting than on licensing a legacy patent estate.
How strong is the patent estate for polyethylene glycol 3350 electrolyte solutions?
The core patent estate is weak from a market-entry perspective because the combination has been used commercially for many years and its active ingredients are old, well-characterized substances.
Core composition protection
A new composition patent covering only PEG 3350 with sodium chloride, potassium chloride and sodium bicarbonate would face significant validity and obviousness risks if the claimed formulation closely tracks an established product. A defensible composition patent would generally need a technically meaningful distinction, such as:
- A materially reduced solution volume.
- A specific concentration range producing improved tolerability or safety.
- A controlled-dissolution powder system.
- A stable, low-moisture formulation with defined shelf life.
- A clinically supported reduction in nausea, vomiting or incomplete cleansing.
- A novel flavor or masking system with measurable adherence benefits.
- A device or package that controls preparation and dosing.
Patentability is stronger when the claim is tied to a defined formulation parameter and a clinically relevant result. Broad claims covering known PEG-electrolyte mixtures are less attractive.
Formulation patents
Formulation patents offer the clearest route to differentiated exclusivity. Potential claim categories include:
| Claim area |
Commercial objective |
Relative patent opportunity |
| Low-volume formulation |
Reduce patient burden |
High if supported by clinical performance |
| Flavor masking |
Improve completion rates |
Moderate |
| Rapid dissolution |
Shorten preparation time |
Moderate |
| Moisture-control packaging |
Extend shelf life |
Moderate |
| Divided-dose presentation |
Improve adherence |
Moderate |
| Ready-to-drink solution |
Eliminate reconstitution |
Moderate to high, depending on technical solution |
| Pediatric formulation |
Improve acceptability and dosing |
Moderate |
| Renal-risk positioning |
Reduce electrolyte complications |
High only with clinical evidence |
A patent on a flavor alone is usually narrower and easier to design around than a patent covering a defined formulation, packaging system and use protocol.
Method-of-use patents
Method-of-use protection could cover bowel cleansing before colonoscopy, split-dose administration, use in patients with particular risk factors or a defined timing regimen. The underlying use is established, so broad method claims would face prior-art challenges.
The strongest method claims would likely require a specific patient population, dosing schedule or clinically validated outcome. Examples include improved cleansing with reduced total volume, improved tolerability in older adults or a protocol designed for patients unable to consume a conventional four-liter preparation.
What excipient strategies can differentiate the product?
The commercial opportunity is not to replace the electrolyte system without evidence. It is to improve the patient experience while preserving cleansing performance and regulatory comparability.
Flavor and odor management
Taste is a major adherence barrier. PEG-electrolyte preparations can be difficult to consume because of saltiness, volume and aftertaste. A differentiated flavor system can use:
- Citrus or berry flavorants.
- Acidulants with controlled buffering.
- Non-nutritive sweeteners.
- Separate flavor sachets.
- Flavor options selected by the patient.
- Odor-masking agents.
- Cooling instructions supported by stability data.
The main technical risk is interaction with bicarbonate and the electrolyte system. Acidulants can alter pH, carbon dioxide generation and stability. Sweeteners and flavor oils can also affect dissolution, microbial risk or container compatibility.
A commercial product should avoid positioning flavor as an unsubstantiated clinical benefit. The stronger strategy is to generate data showing improved completion, lower vomiting rates or better patient satisfaction.
Powder-flow and dissolution excipients
A four-liter formulation contains a high mass of PEG and inorganic salts. Powder handling can create segregation, caking and nonuniformity risks. Suitable excipient and process strategies include:
- Granulation to reduce segregation.
- Particle-size engineering.
- Controlled moisture exposure.
- Anti-caking systems compatible with oral use.
- Sequential blending of PEG and electrolytes.
- Multi-compartment packaging.
- Dissolution aids that do not materially change osmolality or electrolyte delivery.
For a generic product, the safest design usually preserves the established qualitative and quantitative composition. For a differentiated product, the sponsor can seek protection around a process that produces rapid, uniform reconstitution without altering the clinical dose.
Packaging as part of the formulation strategy
Packaging is a high-value area because the product is sensitive to moisture and is used in a large final volume. Commercial formats can include:
- Single large bottles.
- Multi-sachet systems.
- Unit-dose sachets.
- Dual-compartment pouches.
- Pre-measured bottles with fill lines.
- Ready-to-drink containers.
- Packaging with detachable flavor modules.
Multi-sachet packaging can improve supply-chain flexibility and allow a sponsor to sell multiple flavor options. It also creates a risk of patient preparation errors. Clear fill-line instructions, tamper evidence and standardized mixing steps are important regulatory and commercial controls.
What commercial opportunities exist for this formulation?
Low-volume bowel preparation
The largest opportunity is reducing the volume patients must consume. Conventional four-liter PEG-electrolyte products compete against lower-volume products that use additional stimulant or osmotic components.
A lower-volume PEG 3350 formulation would need to address:
- Adequate cleansing.
- Sodium and potassium balance.
- Dehydration risk.
- Renal and cardiac tolerability.
- Nausea and vomiting.
- Compatibility with split-dose regimens.
- Comparable colonoscopy quality.
The commercial reward is substantial because physicians and patients commonly select bowel preparations based on tolerability and completion.
Split-dose and next-day scheduling
Split-dose administration has become a major bowel-preparation practice because it can improve cleansing quality compared with taking the entire preparation the prior evening.[5] A product designed around simpler split-dose instructions, smaller individual portions or better refrigeration and portability could compete without changing the underlying active ingredients.
The patent opportunity is stronger for a combined product-and-regimen package supported by clinical data than for generic instructions alone.
Ready-to-drink products
A ready-to-drink formulation removes the need for patient reconstitution. It can reduce preparation errors and improve convenience, but it increases:
- Shipping weight.
- Packaging cost.
- Microbial-control requirements.
- Stability burden.
- Carbon-footprint exposure.
- Retail and pharmacy storage requirements.
A concentrated liquid requiring dilution may provide a compromise between powder and fully ready-to-drink formats.
Renal and medically complex populations
PEG-electrolyte preparations are often selected when clinicians seek to avoid certain non-PEG bowel preparations, particularly in patients with renal or cardiovascular concerns. This creates a commercial segment for products with carefully controlled electrolyte delivery and explicit use instructions.
Claims regarding safety in chronic kidney disease, heart failure or older adults require clinical substantiation. The regulatory and litigation risk is higher if marketing implies superiority without comparative evidence.
Pediatric and geriatric formats
Pediatric use is commercially attractive because taste and volume are significant barriers. Potential adaptations include:
- Smaller dose volumes based on weight.
- More acceptable flavors.
- Powder packets suitable for caregivers.
- Dosing cups with clear volume markings.
- Reduced nausea and improved palatability.
- Child-resistant but caregiver-friendly packaging.
Older adults may benefit from easier reconstitution, larger labeling, lower physical handling requirements and packaging designed for assisted administration.
How does this product compare with competing bowel preparations?
| Product category |
Active-system profile |
Main commercial advantage |
Main limitation |
| Four-liter PEG-electrolyte solution |
PEG 3350 plus balanced electrolytes |
Established safety and cleansing record |
High volume and poor palatability |
| Low-volume PEG product |
PEG with additional osmotic or stimulant components |
Lower patient burden |
More complex safety and labeling profile |
| Sodium sulfate-based preparation |
Sulfate salts with PEG and other electrolytes |
Lower-volume options |
Electrolyte and renal considerations |
| Sodium picosulfate product |
Stimulant laxative with osmotic salts |
Small volume and palatability |
Hydration and electrolyte management |
| Oral sulfate solution |
Sulfate-based osmotic preparation |
High convenience in some regimens |
Taste and safety restrictions |
The PEG 3350 electrolyte combination retains a defensible clinical position because it is familiar to gastroenterologists and is supported by long market experience. Its weak point is patient burden, not physician recognition.
Which companies are challenging or competing with the product?
The market includes branded and generic manufacturers of PEG-electrolyte solutions, including products marketed under names such as GoLYTELY, NuLYTELY, TriLyte, Colyte and their generic equivalents. The competitive field also includes manufacturers of MoviPrep, Plenvu, SUTAB, Sutab-type sulfate tablets, SUPREP and Clenpiq-type preparations.
Competition is driven by:
- Pharmacy benefit formulary placement.
- Gastroenterology-clinic preference.
- Wholesale acquisition cost.
- Patient copay.
- Availability during procedure season.
- Packaging convenience.
- Taste and completion rates.
- Contracting with health systems and endoscopy centers.
A generic manufacturer can compete with a low-cost conventional powder. A branded challenger needs a patient-experience advantage supported by evidence.
What generic entry risks exist?
Generic entry risk is high for any branded product that lacks active listed patents or regulatory exclusivity. The most likely launch scenarios are:
- A direct generic powder with the same active ingredients and a similar reconstitution profile.
- A lower-cost product with a different flavor system.
- A multi-sachet product that improves manufacturing and distribution.
- A private-label product supplied through a contract manufacturer.
- A lower-volume or ready-to-drink challenger using a differentiated formulation.
Manufacturing barriers are limited but not trivial. The main operational risks are blend uniformity, moisture control, electrolyte assay, package integrity, stability and supply continuity. These barriers can delay launch but rarely prevent a capable generic manufacturer from entering.
What licensing and partnering opportunities are available?
Licensing value is more likely to arise from platform technology than from the legacy combination itself. Attractive assets include:
- Taste-masking technology.
- Low-volume PEG formulations.
- Rapid-dissolution granules.
- Moisture-resistant packaging.
- Ready-to-drink stability systems.
- Pediatric dosing platforms.
- Digital or physical adherence aids.
- Clinical data demonstrating improved completion or cleansing.
A conventional four-liter powder has limited out-licensing appeal unless the asset includes a protected brand, established manufacturing scale or an exclusive distribution channel. A formulation with a granted patent family and comparative clinical data can support regional licensing, co-development or supply agreements.
What revenue exposure does the formulation create?
Revenue exposure depends on product positioning:
| Positioning |
Revenue profile |
| Commodity generic powder |
High volume, low margin |
| Branded four-liter product |
Moderate volume, vulnerable to contracting |
| Premium flavored product |
Moderate volume, higher margin if adherence improves |
| Low-volume formulation |
Higher pricing potential and stronger differentiation |
| Ready-to-drink product |
Premium pricing offset by higher logistics cost |
| Pediatric or specialty product |
Smaller market with potentially higher unit economics |
| Hospital or endoscopy-center supply |
Predictable volume but strong price pressure |
The commercial ceiling for a standard PEG-electrolyte powder is limited by generic substitution. The highest-value opportunity is a clinically validated product that reduces patient burden without creating a substantially more complex safety profile.
Key Takeaways
- PEG 3350 with sodium chloride, potassium chloride and sodium bicarbonate is a mature prescription bowel-prep combination.
- The core ingredients are established, and the main commercial competition is generic.
- Traditional compound patent protection is weak; formulation, packaging and method-of-use patents offer the better protection strategy.
- The strongest opportunities are lower volume, improved taste, rapid dissolution, ready-to-drink delivery and pediatric or geriatric usability.
- The product’s regulatory pathway is familiar, but manufacturing control over powder uniformity, moisture and electrolyte content is essential.
- Generic entry risk is high for a conventional four-liter powder without active Orange Book-listed protection.
- Licensing value depends on differentiated formulation technology and clinical evidence, not on the legacy ingredient combination alone.
- A premium product should prove improved completion, tolerability or cleansing rather than rely only on a new flavor or package design.
Frequently Asked Questions
Is polyethylene glycol 3350 an excipient in this product?
No. In a PEG-electrolyte bowel preparation, polyethylene glycol 3350 is an active osmotic ingredient. Sodium chloride, potassium chloride and sodium bicarbonate are also listed as active ingredients. Conventional excipients are mainly flavorants, sweeteners, processing aids and packaging-related components.
Can a manufacturer patent a new flavor of PEG-electrolyte solution?
Possibly, but flavor-only claims are usually narrow. A stronger patent position may arise when the flavor system is part of a defined formulation that improves stability, dissolution, completion or tolerability.
Is a four-liter PEG-electrolyte solution still commercially viable?
Yes. It remains viable as a low-cost, familiar product, especially in generic and institutional channels. Its main disadvantages are volume, taste and patient adherence.
What is the best commercial route for a branded challenger?
A lower-volume or easier-to-consume product with comparative adherence and cleansing data is more defensible than a conventional four-liter powder with cosmetic flavor changes.
Are biosimilar risks relevant to this product?
No. This is a chemically defined small-molecule combination, not a biologic. Biosimilar pathways do not apply. Competitive risk comes from generic drugs, reformulations and alternative bowel-preparation technologies.
References
-
DailyMed. (2024). GoLYTELY: Polyethylene glycol 3350, sodium chloride, sodium bicarbonate, and potassium chloride for oral solution prescribing information. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: GoLYTELY, NDA 018316. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
American Society for Gastrointestinal Endoscopy. (2015). Optimizing adequacy of bowel cleansing for colonoscopy: Recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 81(1), 5-16.
